Scarica l'app Stockscreener
1.60
2.56%
0.04
Dopo l'orario di chiusura:
1.60
Precedente Chiudi:
$1.56
Aprire:
$1.53
Volume 24 ore:
63,867
Relative Volume:
0.90
Capitalizzazione di mercato:
$90.68M
Reddito:
-
Utile/perdita netta:
$-46.12M
Rapporto P/E:
-2.1425
EPS:
-0.7468
Flusso di cassa netto:
$-41.02M
1 W Prestazione:
+2.24%
1M Prestazione:
+2.56%
6M Prestazione:
+15.94%
1 anno Prestazione:
+15.94%
Intervallo 1D:
$1.52
$1.60
Intervallo di 1 settimana:
$1.49
$1.60
Portata 52W:
$1.14
$2.10
Inflarx N V Stock (IFRX) Company Profile
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-02-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-04-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-01-29 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-10 | Iniziato | Credit Suisse | Outperform |
| 2018-07-13 | Iniziato | BMO Capital Markets | Outperform |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-28 | Iniziato | SunTrust | Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Inflarx N V Borsa (IFRX) Ultime notizie
InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times
InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire
InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat
InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World
InflaRx reports promising HS treatment results at EADV Congress - Investing.com India
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks
InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News
InflaRx reports promising HS treatment results at EADV Congress By Investing.com - Investing.com Australia
InflaRx Announces Participation in September Investor Events - Yahoo Finance UK
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK
InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat
InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World
InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News
InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK
InflaRx presents new preclinical findings for INF904 - TipRanks
InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire
InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx N.V. Reports Mid-Year Financial Results - TipRanks
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks
InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewswire
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewswire
Vasculitis Treatment Market with Tremendous growth by 2031 – Glaxosmithkline plc, Amneal Pharmaceuticals, Inc., ChemoCentryx, InflaRx N.V – TIMC - TIMC
InflaRx (NASDAQ:IFRX) Short Interest Up 151.1% in June - American Banking and Market News
Short Interest in InflaRx (NASDAQ:IFRX) Expands By 151.1% - MarketBeat
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 151.1% - Defense World
InflaRx Announces $75M Share Sales Agreement - TipRanks
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia
InflaRx (NASDAQ:IFRX) Short Interest Update - MarketBeat
What Kind Of Investors Own Most Of InflaRx N.V. (NASDAQ:IFRX)? - Yahoo New Zealand News
SEC Form 424B5 filed by InflaRx N.V. - Quantisnow
InflaRx (NASDAQ:IFRX) Receives “Buy” Rating from HC Wainwright - Defense World
InflaRx's ARDS drug selected for BARDA Phase 2 study - Investing.com India
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Iron Mountain executive sells over $547k in company stock By Investing.com - Investing.com UK
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed ... - WICZ
InflaRx's GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire
InflaRx’s GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire
InflaRx's (IFRX) Buy Rating Reaffirmed at HC Wainwright - Defense World
InflaRx's (IFRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
InflaRx Hosts R&D Event Highlighting the Promise of INF904 - GlobeNewswire
InflaRx (NASDAQ:IFRX) Trading Up 10.5% - MarketBeat
Inflarx N V Azioni (IFRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):